136 related articles for article (PubMed ID: 33751739)
21. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
[TBL] [Abstract][Full Text] [Related]
22. Mixed-methods evaluation of point-of-care hepatitis C virus RNA testing in a Scottish prison.
Byrne CJ; Malaguti A; Inglis SK; Dillon JF
BMJ Open; 2023 Apr; 13(4):e068604. PubMed ID: 37037621
[TBL] [Abstract][Full Text] [Related]
23. Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare professional stakeholders.
Ruiz AS; Fontaine G; Patey AM; Grimshaw JM; Presseau J; Cox J; Dussault C; Kronfli N
Int J Drug Policy; 2022 Nov; 109():103837. PubMed ID: 36030569
[TBL] [Abstract][Full Text] [Related]
24. Detection, stratification and treatment of hepatitis C-positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
Connoley D; Francis-Graham S; Storer M; Ekeke N; Smith C; Macdonald D; Rosenberg W
J Viral Hepat; 2020 Oct; 27(10):987-995. PubMed ID: 32449969
[TBL] [Abstract][Full Text] [Related]
25. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C;
J Viral Hepat; 2018 Dec; 25(12):1526-1532. PubMed ID: 30141261
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C virus infection and its associated factors among prisoners in a Nigerian prison.
Okafor IM; Ugwu SO; Okoroiwu HU
BMC Gastroenterol; 2020 Oct; 20(1):360. PubMed ID: 33126856
[TBL] [Abstract][Full Text] [Related]
27. [Seroprevalence of hepatitis C virus infection at the time of entry to prison in the prison population in the north-east of Spain].
Martín Sánchez V; Ferrer Castro V; Pallas Álvarez JR; Alonso Herrero LE; Andrés Honorato M; Coterillo González MJ; García Marcos LS; González Márquez J; Hernández Alonso I; LLanos Gallegos M; Mallada García E; Martínez Martínez ML; Morillo Pérez M; Pérez Martínez I; Valles Martínez J
Rev Esp Salud Publica; 1998; 72(1):43-51. PubMed ID: 9477715
[TBL] [Abstract][Full Text] [Related]
28. Prison officers' views about hepatitis C testing and treatment: a qualitative enquiry.
Jack K; Islip N; Linsley P; Thomson B; Patterson A
J Clin Nurs; 2017 Jul; 26(13-14):1861-1868. PubMed ID: 27486922
[TBL] [Abstract][Full Text] [Related]
29. Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.
Lafferty L; Treloar C; Guthrie J; Chambers GM; Butler T
J Viral Hepat; 2017 Feb; 24(2):111-116. PubMed ID: 27778436
[TBL] [Abstract][Full Text] [Related]
30. Tattooing in prisons--not such a pretty picture.
Hellard ME; Aitken CK; Hocking JS
Am J Infect Control; 2007 Sep; 35(7):477-80. PubMed ID: 17765561
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR;
Lancet Gastroenterol Hepatol; 2021 May; 6(5):391-400. PubMed ID: 33857445
[TBL] [Abstract][Full Text] [Related]
32. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
[TBL] [Abstract][Full Text] [Related]
33. How do people in prison feel about opt-out hepatitis C virus testing?
Jack K; Linsley P; Thomson BJ; Irving WL
J Viral Hepat; 2020 Oct; 27(10):1003-1011. PubMed ID: 32488916
[TBL] [Abstract][Full Text] [Related]
34. A framework for management of hepatitis C in prisons.
Spaulding AC; Weinbaum CM; Lau DT; Sterling R; Seeff LB; Margolis HS; Hoofnagle JH
Ann Intern Med; 2006 May; 144(10):762-9. PubMed ID: 16702592
[TBL] [Abstract][Full Text] [Related]
35. Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners - 2004, 2007, 2010.
Reekie JM; Levy MH; Richards AH; Wake CJ; Siddall DA; Beasley HM; Kumar S; Butler TG
Med J Aust; 2014 Mar; 200(5):277-80. PubMed ID: 24641153
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration.
Crowley D; Van Hout MC; Murphy C; Kelly E; Lambert JS; Cullen W
Health Justice; 2018 Dec; 6(1):23. PubMed ID: 30569249
[TBL] [Abstract][Full Text] [Related]
37. [Hepatitis C in prisons : Treatment and barriers to the elimination goals of the United Nations].
Dichtl A; Jamin D; Stöver H; Grabski M; Knorr B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Jan; 67(1):36-44. PubMed ID: 38155308
[TBL] [Abstract][Full Text] [Related]
38. Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons.
Bah R; Sheehan Y; Li X; Price N; Butler T; Dore GJ; Grebely J; Lloyd AR; Hajarizadeh B;
Int J Drug Policy; 2024 Apr; ():104401. PubMed ID: 38670855
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
Kwon JA; Chambers GM; Luciani F; Zhang L; Kinathil S; Kim D; Thein HH; Botha W; Thompson S; Lloyd A; Yap L; Gray RT; Butler T
PLoS One; 2021; 16(2):e0245896. PubMed ID: 33571196
[TBL] [Abstract][Full Text] [Related]
40. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
